Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide

R. A. Joss, P. Alberto, J. P. Obrecht, L. Barrelet, E. E. Holdener, P. Siegenthaler, A. Goldhirsch, B. Mermillod, F. Cavalli

Research output: Contribution to journalArticle

Abstract

The combinations of doxorubicin (40 mg/m2 iv every 3 weeks) and mitomycin (12 mg/m2 iv every 6 weeks) or cisplatin (80 mg/m2 iv every 3 weeks x 3, then every 6 weeks) and etoposide (80 mg/m2 iv on Days 1-3 every 3 weeks x 3, then every 6 weeks) were evaluated in a randomized phase II trial in 77 patients with measurable or evaluable non-small cell lung cancer. No patient had been pretreated with prior chemotherapy. The overall response rate for the doxorubicin and mitomycin regimen was 11% and for the cisplatin and etoposide regimen was 23%. Responses lasted a median of 5.5 months. Median survival was 7.0 months for the doxorubicin and mitomycin regimen and 8.0 months for the cisplatin and etoposide regimen. One treatment-related death was observed after doxorubicin and mitomycin in a patient who had received radiation therapy immediately prior to study entry. Otherwise, the hematologic toxicity of both chemotherapy regimens was moderate, with only six patients (10%) having World Health Organization grade 3 toxicity and no patients having World Health Organization grade 4 toxicity. However, subjective tolerance (gastrointestinal upset) of the cisplatin and etoposide combination was poor.

Original languageEnglish
Pages (from-to)1079-1084
Number of pages6
JournalCancer Treatment Reports
Volume68
Issue number9
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide'. Together they form a unique fingerprint.

  • Cite this

    Joss, R. A., Alberto, P., Obrecht, J. P., Barrelet, L., Holdener, E. E., Siegenthaler, P., Goldhirsch, A., Mermillod, B., & Cavalli, F. (1984). Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treatment Reports, 68(9), 1079-1084.